相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emerging therapies in Parkinson disease - repurposed drugs and new approaches
Ahmad Elkouzi et al.
NATURE REVIEWS NEUROLOGY (2019)
Targeting -Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics
Daniel Savitt et al.
DRUGS (2019)
Clinical drug development for dementia with Lewy bodies: past and present
Garam Lee et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Progress of Pharmacological Approaches in Parkinson's Disease
Kirsten L. Zeuner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine
Michele Perni et al.
ACS CHEMICAL BIOLOGY (2018)
Chemical Kinetics for Bridging Molecular Mechanisms and Macroscopic Measurements of Amyloid Fibril Formation
Thomas C. T. Michaels et al.
ANNUAL REVIEW OF PHYSICAL CHEMISTRY, VOL 69 (2018)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Anthony E. Lang et al.
MOVEMENT DISORDERS (2018)
α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies
Iryna Prots et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons
Jordi Pujols et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
SAR by kinetics for drug discovery in protein misfolding diseases
Sean Chia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Potent alpha-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State
Martin Kurnik et al.
CELL CHEMICAL BIOLOGY (2018)
Therapeutic approaches to target alpha-synuclein pathology
Patrik Brundin et al.
EXPERIMENTAL NEUROLOGY (2017)
Zeroing in on neurodegenerative α-synuclein
Katie Kingwell
NATURE REVIEWS DRUG DISCOVERY (2017)
A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
Michele Perni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers
Giuliana Fusco et al.
SCIENCE (2017)
The Synucleinopathies: Twenty Years On
Michel Goedert et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Ultrasensitive Measurement of Ca2+ Influx into Lipid Vesicles Induced by Protein Aggregates
Patrick Flagmeier et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Therapeutic approaches in Parkinson's disease andrelated disorders
Elvira Valera et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Hamiltonian Dynamics of Protein Filament Formation
Thomas C. T. Michaels et al.
PHYSICAL REVIEW LETTERS (2016)
Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation
Patrick Flagmeier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay et al.
LANCET NEUROLOGY (2015)
Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation
Celine Galvagnion et al.
NATURE CHEMICAL BIOLOGY (2015)
Role of filament annealing in the kinetics and thermodynamics of nucleated polymerization
Thomas C. T. Michaels et al.
JOURNAL OF CHEMICAL PHYSICS (2014)
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
Anthony H. V. Schapira et al.
LANCET (2014)
Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation
Alexander K. Buell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Chemical kinetics for drug discovery to combat protein aggregation diseases
Paolo Arosio et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Site-specific Inhibitory Mechanism for Amyloid β42 Aggregation by Catechol-type Flavonoids Targeting the Lys Residues
Mizuho Sato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Toward the Molecular Mechanism(s) by Which EGCG Treatment Remodels Mature Amyloid Fibrils
Fernando L. Palhano et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism
Samuel I. A. Cohen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein
Nunilo Cremades et al.
CELL (2012)
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Iryna Benilova et al.
NATURE NEUROSCIENCE (2012)
FDA-Approved Drugs that Protect Mammalian Neurons from Glucose Toxicity Slow Aging Dependent on Cbp and Protect Against Proteotoxicity
Alex Lublin et al.
PLOS ONE (2011)
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Jacqueline Burre et al.
SCIENCE (2010)
The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds
Sean A. Hudson et al.
FEBS JOURNAL (2009)
An Analytical Solution to the Kinetics of Breakable Filament Assembly
Tuomas P. J. Knowles et al.
SCIENCE (2009)
Autoxidative quinone formation in vitro and metabolite formation in vivo from tea polyphenol (-)-epigallocatechin-3-gallate: Studied by real-time mass spectrometry combined with tandem mass ion mapping
Shengmin Sang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide
Christian Haass et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism
Y Porat et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2006)
α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy
KE Paleologou et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2005)
The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils
M Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
DD Murphy et al.
JOURNAL OF NEUROSCIENCE (2000)
分享论文
